Page 57 - ARNM-2-2

Advances in Radiotherapy
& Nuclear Medicine PET and Compton Camera CZT based system

With these capabilities, our system is in a strong position nanoScan PET/CT and PET/MR for quantitative imaging
18
89
to lead the next generation of hybrid imaging PET devices. of F and Zr as compared with ex vivo biodistribution in
tumor-bearing mice. EJNMMI Res. 2021;11:57.
Acknowledgments doi: 10.1186/s13550-021-00799-2
The authors acknowledge the support of Lars Furenlid and 5. Ferguson S, Jans HS, Wuest M, Riauka T, Wuest F.
Matthew Kupinski of University of Arizona and Michael Comparison of scandium-44 g with other PET radionuclides
King and Sophia Pells of the University of Massachussets. in pre-clinical PET phantom imaging. EJNMMI Phys.
2019;6(1):23.
Funding
doi: 10.1186/s40658-019-0260-0
This study was carried out with the support of the National 6. PSMA PET Scan for Prostate Cancer. Available from: https://
Institute of Biomedical Imaging and Bioengineering of www.uchicagomedicine.org/cancer/types-treatments/
the National Institutes of Health under award numbers prostate-cancer/screening-diagnosis/psma-pet [Last
R01EB028091 and UG3EB034686. accessed on 2023 Nov 29].

Conflict of interest 7. Hoshi S, Yaginuma K, Meguro S, et al. PSMA targeted
molecular imaging and radioligand therapy for prostate
The authors declare that they have no competing interests. cancer: Optimal patient and treatment issues. Curr Oncol.
2023;30(8):7286-7302.
Author contributions
doi: 10.3390/curroncol30080529
Conceptualization: Shiva Abbaszadeh 8. Sutherland DE, Azad AA, Murphy DG, Eapen RS, Kostos L,
Formal Analysis: Greyson Shoop Hofman MS. Role of FDG PET/CT in management of patients
Investigation: Greyson Shoop with prostate cancer. Semin Nucl Med. 2024;54(1):4-13.
Methodology: Shiva Abbaszadeh
Writing – original draft: Greyson Shoop doi: 10.1053/j.semnuclmed.2023.06.005
Writing – review & editing: All authors 9. Kuzmenko NK. Updated decay data evaluation for Ga.
68
Appl Radiat Isot. 2019;152:188-192.
Ethics approval and consent to participate doi: 10.1016/j.apradiso.2019.07.008
Not applicable. 10. Piron S, Verhoeven J, Descamps B, et al. Intra-individual
dynamic comparison of F-PSMA-11 and Ga-PSMA-11 in
18
68
Consent for publication LNCaP xenograft bearing mice. Sci Rep. 2020;10(1):21068.
Not applicable. doi: 10.1038/s41598-020-78273-7
18
Availability of data 11. Huang S, Ong S, McKenzie D, et al. Comparison of F-based
PSMA radiotracers with [ Ga]Ga-PSMA-11 in PET/CT
68
Data are available from the corresponding author upon imaging of prostate cancer-a systematic review and meta-
request. analysis. Prostate Cancer Prostatic Dis. 2023:1-11.
References doi: 10.1038/s41391-023-00755-2
12. Roberts MJ, Maurer T, Perera M, et al. Using PSMA imaging
1. Dolgin E. Radioactive drugs emerge from the shadows to for prognostication in localized and advanced prostate
storm the market. Nat Biotechnol. 2018;36(12):1125-1127.
cancer. Nat Rev Urol. 2023;20(1):23-47.
doi: 10.1038/nbt1218-1125
doi: 10.1038/s41585-022-00670-6
2. Bodei L, Herrmann K, Schöder H, Scott AM, Lewis JS. 13. George SC, Samuel EJ. Developments in 177 Lu-based
Radiotheranostics in oncology: Current challenges radiopharmaceutical therapy and dosimetry. Front Chem.
and emerging opportunities. Nat Rev Clin Oncol. 2023;11:1218670.
2022;19(8):534-550.
doi: 10.3389/fchem.2023.1218670.
doi: 10.1038/s41571-022-00652-y
14. Carter LM, Kesner AL, Pratt EC, et al. The impact of
3. Sgouros G, Bodei L, McDevitt MR, Nedrow JR. positron range on PET resolution, evaluated with phantoms
Radiopharmaceutical therapy in cancer: Clinical advances and PHITS monte carlo simulations for conventional
and challenges. Nat Rev Drug Discov. 2020;19(9):589-608.
and non-conventional radionuclides. Mol Imaging Biol.
doi: 10.1038/s41573-020-0073-9 2020;22(1):73-84.
4. Chomet M, Schreurs M, Vos R, et al. Performance of doi: 10.1007/s11307-019-01337-2

Volume 2 Issue 2 (2024) 11 doi: 10.36922/arnm.3330